Portfolio Company:


Qrono immunoengineering technology to address tumor-immunity in cancer patients

Qrono is actively developing patentable therapies that change cancer-immune cell communication.  Their aim is to create cost-effective, low-toxicity treatment options for activating anti-cancer immune cells or for turning “cold” tumors “hot”, outcomes which are rarely realized for patients on current chemo- or immunotherapies.

Portfolio news